| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
|
Fenofibric Acid is an active metabolite of fenofibrate, which is a PPAR activitor, with EC50s of 22.4 µM, 1.47 µM, and 1.06 µM for PPARα, PPARγ and PPARδ, respectively.
| ln Vitro |
With EC50 values of 22.4 µM, 1.47 µM, and 1.06 µM for PPARα, PPARγ, and PPARδ, respectively, fenofibric acid is a PPAR activator[1]. With an IC50 of 48 nM, fenofibric acid (10, 25, 50, 75, and 100 nM) dose-dependently inhibits the COX-2 enzyme [2]. In HepG2 cells, the quantity of AOX1 protein is decreased by 500 nM of fenofibric acid [3]. At a concentration of 100 µM, fenofibric acid inhibits the phosphorylation of JNK1/2, c-Jun, and p38 MAPK. Additionally, it prevents the buildup of reactive oxygen species, endoplasmic reticulum stress, and disruption of the blood-retina barrier (BRB). ARPE-19 cells exhibit hypoxia and high glucose (HG). In ARPE-19 cells exposed to hypoxia and HG conditions, fenofibric acid (100 µM) triggers the IGF-IR/Akt/ERK1/2-mediated survival signaling pathway [4].
|
|---|---|
| ln Vivo |
Fenofibric Acid (1, 5, 10 mg/kg, oral) shows anti-inflammatory action against carrageenan-induced acute inflammation in Wistar rats [2].
|
| References |
[1]. Dietz M, et al. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem. 2012 Jun;7(6):1101-11.
[2]. Prasad GS, et al. Anti-inflammatory activity of anti-hyperlipidemic drug, fenofibrate, and its phase-I metabolite fenofibric acid: in silico, in vitro, and in vivo studies. Inflammopharmacology. 2017 Dec 13. [3]. Neumeier M, et al. Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. Biochem Biophys Res Commun. 2006 Nov 24;350(3):731-5. Epub 2006 Sep 27. [4]. Miranda S, et al. Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. J Cell Physiol. 2012 Jun;227(6):2352-62 |
| Molecular Formula |
C17H15O4CL
|
|---|---|
| Molecular Weight |
318.7516
|
| CAS # |
42017-89-0
|
| Related CAS # |
Choline Fenofibrate;856676-23-8;Fenofibric acid (Standard);42017-89-0;Fenofibric acid-d6;1092484-69-9
|
| SMILES |
CC(C)(OC1=CC=C(C(C2=CC=C(Cl)C=C2)=O)C=C1)C(O)=O
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~313.73 mM)
H2O : ~1 mg/mL (~3.14 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1373 mL | 15.6863 mL | 31.3725 mL | |
| 5 mM | 0.6275 mL | 3.1373 mL | 6.2745 mL | |
| 10 mM | 0.3137 mL | 1.5686 mL | 3.1373 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
